Literature DB >> 17182170

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?

Gero Kramer1, Dieter Mitteregger, Michael Marberger.   

Abstract

OBJECTIVES: Chronic inflammation has been documented for years in benign prostatic hyperplasia (BPH), but only now has it become evident as a major factor in disease progression. This review highlights the immunologic key features of chronic inflammation in BPH and the present interpretation of these changes in the development and progression of BPH.
RESULTS: Almost all BPH specimens show inflammatory infiltrates at histologic examination, but correlation to bacterial or other foreign antigens has not been established. Recognition of prostate secretion products by autoreactive T cells and animal models on experimental prostatitis demonstrate an autoimmune component to chronic inflammation. The infiltrate consists predominantly of chronically activated CD4(+) T lymphocytes, which are permanently recruited to prostate tissue via elevated expression of interleukin 15 (IL-15) and interferon gamma (IFN-gamma), proinflammatory cytokines produced by smooth muscle and T cells, respectively. With the appearance of infiltrates, T cell-derived cytokine production of IFN-gamma, IL-2, and transforming growth factor beta increases, the former two ultimately reaching 10-fold and the latter 2-fold higher levels in fully developed BPH than in normal prostates. As "mature" BPH nodules develop, IL-4 and IL-13 expression increases >2-fold, corresponding to a T-helper (Th)0/Th2 cytokine pattern. Dysregulation of the immune response in BPH may occur via elevated expression of proinflammatory IL-17, which stimulates a multifold production of IL-6 and IL-8, key executors of stromal growth in BPH.
CONCLUSIONS: These data strongly suggest that BPH is an immune inflammatory disease. Unravelling the specific nature of immune dysregulation may help design novel drugs with these specific targets in mind.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17182170     DOI: 10.1016/j.eururo.2006.12.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  156 in total

1.  [Chronic inflammation as promotor and treatment target in benign prostate hyperplasia (BPH) and in prostate cancer].

Authors:  G Kramer; D Mitteregger; A Maj-Hes; S Sevchenco; W Brozek
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

2.  A call for HoLEP: en-bloc vs. two-lobe vs. three-lobe.

Authors:  Frank Rücker; Karin Lehrich; Axel Böhme; Mario Zacharias; Sascha A Ahyai; Jens Hansen
Journal:  World J Urol       Date:  2021-01-24       Impact factor: 4.226

Review 3.  Mesenchymal stem cells and the embryonic reawakening theory of BPH.

Authors:  W Nathaniel Brennen; John T Isaacs
Journal:  Nat Rev Urol       Date:  2018-11       Impact factor: 14.432

Review 4.  Dietary patterns, supplement use, and the risk of benign prostatic hyperplasia.

Authors:  Kenneth S Poon; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

5.  Nutraceuticals in Prostate Disease: The Urologist's Role.

Authors:  J Curtis Nickel; Daniel Shoskes; Claus G Roehrborn; Mark Moyad
Journal:  Rev Urol       Date:  2008

6.  Curcumin for the Treatment of Prostate Diseases: A Systematic Review of Controlled Clinical Trials.

Authors:  Mohammad Bagherniya; Gholamreza Askari; Babak Alikiaii; Saeed Abbasi; Davood Soleimani; Thozhukat Sathyapalan; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

7.  Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.

Authors:  Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Journal:  Prostate       Date:  2010-04-01       Impact factor: 4.104

8.  Obesity-induced diabetes and lower urinary tract fibrosis promote urinary voiding dysfunction in a mouse model.

Authors:  Mehrnaz Gharaee-Kermani; Jose A Rodriguez-Nieves; Rohit Mehra; Chad A Vezina; Aruna V Sarma; Jill A Macoska
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

9.  A signaling network in phenylephrine-induced benign prostatic hyperplasia.

Authors:  Jayoung Kim; Yutaka Yanagihara; Tadahiko Kikugawa; Mihee Ji; Nozomu Tanji; Yokoyama Masayoshi; Michael R Freeman
Journal:  Endocrinology       Date:  2009-05-14       Impact factor: 4.736

10.  The Roles of Tight Junctions and Claudin-1 in the Microbubble-Mediated Ultrasound-Induced Enhancement of Drug Concentrations in Rat Prostate.

Authors:  Yonggang Shang; Xiaoxiao Dong; Guangwei Han; Jia Li; Dong Cui; Chengcheng Liu; Longkun Li; Shanhong Yi
Journal:  J Membr Biol       Date:  2015-08-20       Impact factor: 1.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.